HAE maker

Why Shire thinks it's done buying assets in HAE

The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs.

The final deal came last week, when Shire announced plans to buy Dyax

Read the full 457 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers